An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ligand Pharmaceuticals Incorporated (LGND) will report its first quarter 2024 financial results on May 7, 2024, after the close of the U.S. financial markets. A conference call will be held at 4:30 p.m. Eastern Time to discuss the results and provide a business update.
Ligand Pharmaceuticals Incorporated (LGND) pubblicherà i risultati finanziari del primo trimestre del 2024 il 7 maggio 2024, dopo la chiusura dei mercati finanziari statunitensi. Si terrà una conferenza telefonica alle 16:30, ora della costa orientale, per discutere i risultati e fornire un aggiornamento sulle attività aziendali.
Ligand Pharmaceuticals Incorporated (LGND) informará sus resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024, tras el cierre de los mercados financieros de EE. UU. Se realizará una llamada de conferencia a las 4:30 p.m., hora del Este, para discutir los resultados y proporcionar una actualización sobre el negocio.
리간드 파마슈티컬스(LGND)는 2024년 1분기 재무 결과를 2024년 5월 7일, 미국 금융 시장 폐장 후에 발표할 예정입니다. 결과를 논의하고 사업 업데이트를 제공하기 위해 동부 표준시로 오후 4시 30분에 컨퍼런스 콜이 개최될 예정입니다.
Ligand Pharmaceuticals Incorporated (LGND) communiquera ses résultats financiers pour le premier trimestre 2024 le 7 mai 2024, après la clôture des marchés financiers américains. Une conférence téléphonique aura lieu à 16h30, heure de l'Est, pour discuter des résultats et fournir une mise à jour sur les affaires de l'entreprise.
Ligand Pharmaceuticals Incorporated (LGND) wird am 7. Mai 2024, nach Börsenschluss in den USA, seine Finanzergebnisse für das erste Quartal 2024 bekannt geben. Eine Telefonkonferenz findet um 16:30 Uhr Ostküstenzeit statt, um die Ergebnisse zu erörtern und ein Geschäftsupdate zu geben.
Positive
None.
Negative
None.
JUPITER, Fla.--(BUSINESS WIRE)--
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.
Conference Call and Webcast Information
Date:
Tuesday, May 7, 2024
Time:
4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Conference Call:
(800) 715-9871 (U.S. & Canada)
(646) 307-1963 (International)
Conference ID is 8755336
Webcast:
Live and replay webcasts of the call are available here.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
When will Ligand Pharmaceuticals (LGND) report its first quarter 2024 financial results?
Ligand Pharmaceuticals (LGND) will report its first quarter 2024 financial results on May 7, 2024, after the close of the U.S. financial markets.
What time is the conference call to discuss Ligand Pharmaceuticals (LGND) financial results?
The conference call to discuss Ligand Pharmaceuticals (LGND) financial results will be held at 4:30 p.m. Eastern Time on May 7, 2024.
How can I listen to the conference call for Ligand Pharmaceuticals (LGND) financial results?
You can listen to the conference call for Ligand Pharmaceuticals (LGND) financial results by dialing (800) 715-9871 (U.S. & Canada) or (646) 307-1963 (International) with conference ID 8755336, or by accessing the live and replay webcasts available on their website.
ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.
